...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Updates
Reply New Message
Prev Message Back To Forum Threaded View Next Message

And, with a successful IND and a Phase I about to start, the company is in a much stronger position to negotiate. Contrast that with 2014 when the company suspended clinical development of ZEN-3365.

5 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply